Skip to main content
. 2023 Nov 17;9(11):e21893. doi: 10.1016/j.heliyon.2023.e21893

Fig. 4.

Fig. 4

THP-1 MΦ infected with viable SARS-CoV-2 variants of concern, MOI: 0.005: (A) B.1.1.7., (B) B.1.351, (C) B.1.1.7.-E484K (D) B.1.617 and treated with TLR4 inhibitor TAK-242 (10 μM). E: Wildtype, TLR4 deleted and MyD88 deleted THP-1 MΦ were infected with viable SARS-CoV-2 omicron variant (B.1.1.529, MOI: 0.005) and TLR4 agonist LPS (10 ng/mL). After 24h, IL-6 expression was quantified by qRT-PCR. Graphs show mean ± SD. (del.: deleted; TLR: toll-like receptor; MyD88: Myeloid differentiation primary response 88).